Operation Linebacker

ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2023

Retrieved on: 
Thursday, August 10, 2023
Nebula, Mayo Clinic, CPT, Marketing, Internet, George Church, Science, Stella, Nebula Genomics, Patient, Whole genome sequencing, Hospital Insurance and Diagnostic Services Act, Three Months, Automation, HRSA, Heart, Therapy, Diagnosis, Hope, Research, Endoscopy, COVID-19 testing, CLIA, Corporation, Medicine, Genetic, Growth, Prophase, System, CDX, IND, Exercise, DNA, Operation Linebacker, Absorption, History, Genetics, Algorithm, FDM, Omicron, Negotiation, Genomics, Cold, Sale, Public expenditure, Genetic counseling, EBITDA, Food, Renewable energy, Pharmaceutical industry, Retail, Cryptocurrency, Tourism, Fine chemical, Vaccine, Microscope, Q2, COVID-19, Bosc

Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three months ended June 30, 2023. The Company announced that despite the slowdown in the Covid-19 testing business, and the significant ramp-up of its multiple growth-oriented subsidiaries, adjusted EBITDA loss for the quarter ended June 30,2023 was $2.2 million in Q2 and that the Company enjoys robust net working capital of $40.2 million as of June 30, 2023.

Key Points: 
  • Company to hold a conference call Thursday, August 10, 2023, at 11:00 AM ET
    Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three months ended June 30, 2023.
  • Revenues grew greater than 100% year-over-year for the six months ended June 30, 2023 as compared to the six months ended June 30, 2022.
  • Three Months Ended June 30, 2023 as compared to the Three Months Ended June 30, 2022.
  • Diagnostic services costs for the three months ended June 30, 2023 were $0.6 million compared to $1.8 million for the three months ended June 30, 2022.